Biosynth Information

Securing Life Sciences Supply Chains - where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. CRB became Biosynth on June 8th 2023. Please follow our page www.linkedin.com/company/biosynth and at www.biosynth.com. Our core business is the chemical synthesis of bespoke peptides and the custom production of polyclonal and monoclonal antibodies. As the second oldest peptide company in the world, Cambridge Research Biochemicals (CRB) supports discovery worldwide and is dedicated to meeting and exceeding customer requirements. Placing our customers at the heart of everything we do, our clients can enjoy an excellent service tailored to their needs. Our experienced technical staff will work with you, providing quality advice on any of your projects; whether to help design optimum protocols to raise your antibodies or to help you select an appropriate dye for fluorescently labelled peptides. CRB offers technical advice and expertise to develop high quality and high affinity Target™ antibodies to specific protein regions and motifs using peptides and provides antigen design free of charge. For 25 years, our team have been producing custom polyclonal and monoclonal antibodies often to specific targets such as phosphorylation sites. CRB joined the Biosynth Group in 2023, offering our customers a wider range of peptide and antibody services including GMP production and lead discovery. Biosynth are experts in products and services where chemistry meets biology, operating across key areas of Complex Chemicals, Peptides and Biologics.